MP CARDIOFLOW-B (02160) Shareholder Deposits Shares into Yunfeng Securities, Portfolio Value Reaches HK$651 Million

Stock News

Jan 22

Latest data from the Hong Kong Stock Exchange reveals that on January 21, a shareholder of MP CARDIOFLOW-B (02160) deposited shares into Yunfeng Securities. The deposited portfolio was valued at HK$651 million, representing a 9.56% stake.

MP CARDIOFLOW announced the official release of one-year follow-up results from the early feasibility study for AltaValveTM, a transcatheter mitral valve replacement (TMVR) medical device independently developed by its associated company, 4C Medical Technologies, Inc. (4C Medical). This multicenter study spanned Europe, the United States, and Japan, enrolling 30 patients who were all at high surgical risk and had symptomatic severe mitral regurgitation (MR). Among the participants, 13 patients were treated using a transapical approach, while 17 received treatment via a transeptal approach.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170129246"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170129246\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170129246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 08:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170129246","market":"nz","top_or_hot":-1,"title":"MP CARDIOFLOW-B (02160) Shareholder Deposits Shares into Yunfeng Securities, Portfolio Value Reaches HK$651 Million","media":"Stock News","content":"<p>Latest data from the Hong Kong Stock Exchange reveals that on January 21, a shareholder of MP CARDIOFLOW-B (02160) deposited shares into Yunfeng Securities. The deposited portfolio was valued at HK$651 million, representing a 9.56% stake.</p>\n<p>MP CARDIOFLOW announced the official release of one-year follow-up results from the early feasibility study for AltaValveTM, a transcatheter mitral valve replacement (TMVR) medical device independently developed by its associated company, 4C Medical Technologies, Inc. (4C Medical). This multicenter study spanned Europe, the United States, and Japan, enrolling 30 patients who were all at high surgical risk and had symptomatic severe mitral regurgitation (MR). Among the participants, 13 patients were treated using a transapical approach, while 17 received treatment via a transeptal approach.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MP CARDIOFLOW-B (02160) Shareholder Deposits Shares into Yunfeng Securities, Portfolio Value Reaches HK$651 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMP CARDIOFLOW-B (02160) Shareholder Deposits Shares into Yunfeng Securities, Portfolio Value Reaches HK$651 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-22 08:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Latest data from the Hong Kong Stock Exchange reveals that on January 21, a shareholder of MP CARDIOFLOW-B (02160) deposited shares into Yunfeng Securities. The deposited portfolio was valued at HK$651 million, representing a 9.56% stake.</p>\n<p>MP CARDIOFLOW announced the official release of one-year follow-up results from the early feasibility study for AltaValveTM, a transcatheter mitral valve replacement (TMVR) medical device independently developed by its associated company, 4C Medical Technologies, Inc. (4C Medical). This multicenter study spanned Europe, the United States, and Japan, enrolling 30 patients who were all at high surgical risk and had symptomatic severe mitral regurgitation (MR). Among the participants, 13 patients were treated using a transapical approach, while 17 received treatment via a transeptal approach.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02160","symbol_name":"微创心通-B","start_time":0,"source_url":"","article_id":"1170129246","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170129246","pubTimestamp":1769041633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Latest data from the Hong Kong Stock Exchange reveals that on January 21, a shareholder of MP CARDIOFLOW-B (02160) deposited shares into Yunfeng Securities. The deposited portfolio was valued at...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","02160":"微创心通-B","BK1583":"高瓴概念","BK1100":"医疗保健设备","BK1574":"生物医药B类股"},"translate_title":"MP心通-B(02160)股东将股份存入云峰证券，组合价值达6.51亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"02160":1},"content_text":"Latest data from the Hong Kong Stock Exchange reveals that on January 21, a shareholder of MP CARDIOFLOW-B (02160) deposited shares into Yunfeng Securities. The deposited portfolio was valued at HK$651 million, representing a 9.56% stake.\nMP CARDIOFLOW announced the official release of one-year follow-up results from the early feasibility study for AltaValveTM, a transcatheter mitral valve replacement (TMVR) medical device independently developed by its associated company, 4C Medical Technologies, Inc. (4C Medical). This multicenter study spanned Europe, the United States, and Japan, enrolling 30 patients who were all at high surgical risk and had symptomatic severe mitral regurgitation (MR). Among the participants, 13 patients were treated using a transapical approach, while 17 received treatment via a transeptal approach.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}